Cipla Loses Trademark Dispute Against Adcock Ingram in South African High Court

In a recent decision by the High Court of South Africa, Indian pharmaceutical giant Cipla has encountered a setback in its trademark battle against South African competitor Adcock Ingram. Justice James Lekhuleni ruled that Cipla’s antibiotic trademark, FURIZOME, bears too close a resemblance to Adcock Ingram’s URIZONE. The court found that the similarity between the names could potentially result in public confusion or deception, as both antibiotics are designed to treat urinary tract infections. For more detailed information, read the full article on Law.com.